Literature DB >> 28835975

[Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017].

M Koziolek1, J Beige2,3, M Wallbach4, D Zenker5, G Henning6, M Halbach7, N Mader8, F Mahfoud9,10, G Schlieper11, V Schwenger12, M Hausberg13, J Börgel14, M Lodde14, M van der Giet15, J Müller-Ehmsen16, J Passauer17, S Parmentier17, S Lüders18, B K Krämer19, S Büttner20, F Limbourg21, J Jordan22, O Vonend23, H-G Predel24, H Reuter7.   

Abstract

Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.

Entities:  

Keywords:  Baroreflex; Blood pressure decrease; Efficacy; Organoprotection; Safety

Mesh：

Year:  2017        PMID： 28835975     DOI： 10.1007/s00108-017-0308-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  38 in total

1.  Prolonged activation of the baroreflex abolishes obesity-induced hypertension.

Authors:  Thomas E Lohmeier; Terry M Dwyer; Eric D Irwin; Martin A Rossing; Robert S Kieval
Journal:  Hypertension       Date:  2007-04-16       Impact factor: 10.190

2.  Baroreflex activation therapy in patients with prior renal denervation.

Authors:  Manuel Wallbach; Marcel Halbach; Hannes Reuter; Jens Passauer; Stephan Lüders; Enrico Böhning; Dieter Zenker; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  J Hypertens       Date:  2016-08       Impact factor: 4.844

3.  Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence.

Authors:  Jan Börgel; Stephanie Springer; Jasmin Ghafoor; Daniel Arndt; Hans-Werner Duchna; Andreas Barthel; Sibylle Werner; Josef Van Helden; Christoph Hanefeld; Horst Neubauer; Daniel Bulut; Andreas Mügge
Journal:  Clin Res Cardiol       Date:  2010-04-02       Impact factor: 5.460

4.  Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure.

Authors:  H P Brunner-La Rocca; M D Esler; G L Jennings; D M Kaye
Journal:  Eur Heart J       Date:  2001-07       Impact factor: 29.983

5.  Impact of baroreflex activation therapy on renal function--a pilot study.

Authors:  Manuel Wallbach; Luca-Yves Lehnig; Charlotte Schroer; Gerd Hasenfuss; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Am J Nephrol       Date:  2014-10-29       Impact factor: 3.754

6.  Role of Chemoreceptor Activation in Hemodynamic Responses to Electrical Stimulation of the Carotid Sinus in Conscious Rats.

Authors:  Pedro L Katayama; Jaci A Castania; Daniel P M Dias; Kaushik P Patel; Rubens Fazan; Helio C Salgado
Journal:  Hypertension       Date:  2015-07-20       Impact factor: 10.190

7.  Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension.

Authors:  Teba Alnima; Peter W de Leeuw; Frans E S Tan; Abraham A Kroon
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

8.  Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension.

Authors:  Kerstin Wustmann; Jan P Kucera; Ingrid Scheffers; Markus Mohaupt; Abraham A Kroon; Peter W de Leeuw; Jürg Schmidli; Yves Allemann; Etienne Delacrétaz
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

9.  Baroreflex activation therapy in patients with end-stage renal failure: proof of concept.

Authors:  Joachim Beige; Michael J Koziolek; Gert Hennig; Amir Hamza; Ralph Wendt; Gerhard A Müller; Manuel Wallbach
Journal:  J Hypertens       Date:  2015-11       Impact factor: 4.844

10.  Prolonged activation of the baroreflex produces sustained hypotension.

Authors:  Thomas E Lohmeier; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190
View more
  6 in total

Review 1.  [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].

Authors:  M Wallbach; M J Koziolek; R Wachter
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

2.  [Therapy-resistant and therapy-refractory arterial hypertension].

Authors:  M Wallbach; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

3.  Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension.

Authors:  Manuel Wallbach; Petra Zürbig; Hassan Dihazi; Gerhard A Müller; Rolf Wachter; Joachim Beige; Michael J Koziolek; Harald Mischak
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-10       Impact factor: 3.738

Review 4.  Implant-Mediated Therapy of Arterial Hypertension.

Authors:  Mortimer Gierthmuehlen; Dennis T T Plachta; Josef Zentner
Journal:  Curr Hypertens Rep       Date:  2020-02-06       Impact factor: 5.369

5.  Impact of medication adherence on the efficacy of Baroreflex activation therapy.

Authors:  Ann-Kathrin C Schäfer; Dieter Müller; Ellen Born; Maria Mühlhaus; Stephan Lüders; Manuel Wallbach; Michael J Koziolek
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-07-23       Impact factor: 2.885

6.  Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension.

Authors:  Ann-Kathrin Schäfer; Tim Kuczera; Rebecca Wurm-Kuczera; Dieter Müller; Ellen Born; Mark Lipphardt; Marlene Plüss; Manuel Wallbach; Michael Koziolek
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-08       Impact factor: 3.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.